Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Prescription Drug User Fee Act (“PDUFA”) goal date of January 3, 2024 FDA indicates that it does not currently plan to hold an advisory committee meeting WALTHAM, Mass., March 02, 2023 (GLOBE...

Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma WALTHAM, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...

InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma In vilobelimab and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concernsSteering Committee unanimously voted to...

SNIA Cloud Data Management Interface Specification Earns ISO/IEC Designation as an International Standard SANTA CLARA, CA--(Marketwire - Oct 16, 2012) - SNW Fall 2012 -- The Storage Networking Industry Association (SNIA) today announced that its Cloud Data Management Interface (CDMI)...

SNIA and the Cloud Standards Customer Council Form Alliance SAN FRANCISCO, CA--(Marketwire - Sep 10, 2012) - News Summary: SNIA and the Cloud Standards Customer Council to collaborate to help ensure technical...